Erratum: YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression (Nature Communications (2014) 5 (4629) DOI: 10.1038/ncomms5629);YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression

Nature Communications

Volumn 5, Issue , 2014, Pages

  Gao, Yijun ^a   Zhang, Wenjing ^a   Han, Xiangkun ^a   Li, Fuming ^a   Wang, Xujun ^b   Wang, Rui ^c   Fang, Zhaoyuan ^a   Tong, Xinyuan ^a   Yao, Shun ^a   Li, Fei ^a   Feng, Yan ^a   Sun, Yihua ^c   Hou, Yingyong ^d   Yang, Zhongzhou ^e   Guan, Kunliang ^f   Chen, Haiquan ^c   Zhang, Lei ^a   Ji, Hongbin ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b TONGJI UNIVERSITY   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d FUDAN UNIVERSITY   (China)

^e NANJING UNIVERSITY   (China)

^f San Diego   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNP63 PROTEIN; PROTEIN; PROTEIN KINASE LKB1; SHORT HAIRPIN RNA; TAMOXIFEN; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; ZEB2 PROTEIN; HOMEODOMAIN PROTEIN; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; REPRESSOR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; STK11 PROTEIN, HUMAN; STK11 PROTEIN, MOUSE; TP63 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; TRP63 PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN; YAP PROTEIN, MOUSE; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN; ZEB2 PROTEIN, HUMAN; ZFHX1B PROTEIN, MOUSE;

CANCER; CELL ORGANELLE; GENE EXPRESSION; INHIBITION; PATHOLOGY; PHENOTYPE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL; CELL ACTIVATION; CELL FATE; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUCIFERASE ASSAY; LUNG ADENOCARCINOMA; MALE; MOUSE; NONHUMAN; PHENOTYPIC PLASTICITY; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TRANSACTIVATION; UPREGULATION; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; DEFICIENCY; DISEASE MODEL; DOWN REGULATION; GENETICS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL TRANSDIFFERENTIATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; PHOSPHOPROTEINS; PROTEIN-SERINE-THREONINE KINASES; REPRESSOR PROTEINS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84907359969     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7459     Document Type: Erratum

References (49)

1. Edgar, B. A. From cell structure to transcription: Hippo forges a new path. Cell 124, 267-273 (2006). (Pubitemid 43121976)
2. Nolo, R., Morrison, C. M., Tao, C. Y., Zhang, X. W. & Halder, G. The bantam microRNA is a target of the hippo tumor-suppressor pathway. Curr. Biol. 16, 1895-1904 (2006). (Pubitemid 44486764)
3. Zhao, B., Lei, Q.-Y. & Guan, K.-L. The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr. Opin. Cell Biol. 20, 638-646 (2008).
4. Zhao, B., Tumaneng, K. & Guan, K. L. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat. Cell Biol. 13, 877-883 (2011).
5. Nishioka, N. et al. The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. Dev. Cell 16, 398-410 (2009).
6. Leung, C. Y. & Zernicka-Goetz, M. Angiomotin prevents pluripotent lineage differentiation in mouse embryos via Hippo pathway-dependent and -independent mechanisms. Nat. Commun. 4, 2251 (2013).
7. Hiemer, S. E. & Varelas, X. Stem cell regulation by the Hippo pathway. Biochim. Biophys. Acta 1830, 2323-2334 (2013).
8. Barry, E. R. & Camargo, F. D. The Hippo superhighway: signaling crossroads converging on the Hippo/Yap pathway in stem cells and development. Curr. Opin. Cell Biol. 25, 247-253 (2013).
9. Schlegelmilch, K. et al. Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell 144, 782-795 (2011).
10. Harvey, K. F., Zhang, X. & Thomas, D. M. The Hippo pathway and human cancer. Nat. Rev. Cancer 13, 246-257 (2013).
11. Steinhardt, A. A. et al. Expression of Yes-associated protein in common solid tumors. Hum. Pathol. 39, 1582-1589 (2008).
12. Xu, M. Z. et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 115, 4576-4585 (2009).
13. Wang, Y. et al. Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci. 101, 1279-1285.
14. Overholtzer, M. et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc. Natl Acad. Sci. USA 103, 12405-12410 (2006). (Pubitemid 44267272)
15. Dong, J. et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130, 1120-1133 (2007). (Pubitemid 47410268)
16. Zhou, D. et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16, 425-438 (2009).
17. Han, X. et al. Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. Nat. Commun. 5, 3261 (2014).
18. Serrano, I., McDonald, P. C., Lock, F., Muller, W. J. & Dedhar, S. Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nat. Commun. 4, 2976 (2013).
19. Sutherland, K. D. & Berns, A. Cell of origin of lung cancer. Mol. Oncol. 4, 397-403 (2010).
20. Meuwissen, R. & Berns, A. Mouse models for human lung cancer. Genes Dev. 19, 643-664 (2005). (Pubitemid 40395076)
21. Ji, H. et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 448, 807-810 (2007). (Pubitemid 47266337)
22. Lau, A. N. et al. Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J. 33, 468-481 (2014).
23. Xie, M. et al. Prognostic significance of TAZ expression in resected non-small cell lung cancer. J. Thorac. Oncol. 7, 799-807 (2012).
24. Zhou, Z. et al. TAZ is a novel oncogene in non-small cell lung cancer. Oncogene 30, 2181-2186 (2011).
25. Calvo, F. et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat. Cell Biol. 15, 637-646 (2013).
26. Dupont, S. et al. Role of YAP/TAZ in mechanotransduction. Nature 474, 179-183 (2011).
27. Zhao, B. et al. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 26, 54-68 (2012).
28. Vandewalle, C. et al. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res. 33, 6566-6578 (2005). (Pubitemid 41806421)
29. Littlewood, T. D., Hancock, D. C., Danielian, P. S., Parker, M. G. & Evan, G. I. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23, 1686-1690 (1995).
30. Visvader, J. E. Cells of origin in cancer. Nature 469, 314-322 (2011).
31. Blanpain, C. Tracing the cellular origin of cancer. Nat. Cell Biol. 15, 126-134 (2013).
32. Wang, R. et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468, 829-833 (2010).
33. Ricci-Vitiani, L. et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468, 824-828 (2010).
34. Snyder, E. L. et al. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol. Cell 50, 185-199 (2013).
35. Shu, C. et al. Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung. Mod. Pathol. 26, 239-246 (2013).
36. Jia, X. L. & Chen, G. EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung. Lung Cancer 74, 396-400 (2011).
37. Kang, S. M. et al. Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer 109, 581-587 (2007). (Pubitemid 46190967)
38. Niho, S., Yokose, T., Kodama, T., Nishiwaki, Y. & Mukai, K. Clonal analysis of adenosquamous carcinoma of the lung. Jpn J. Cancer Res. 90, 1244-1247 (1999).
39. Shiozawa, T. et al. Clinicopathological characteristics of EGFR mutated adenosquamous carcinoma of the lung. Pathol. Int. 63, 77-84 (2013).
40. King, K. E. & Weinberg, W. C. p63: defining roles in morphogenesis, homeostasis, and neoplasia of the epidermis. Mol. Carcinog. 46, 716-724 (2007). (Pubitemid 47255193)
41. Westfall, M. D. & Pietenpol, J. A. p63: Molecular complexity in development and cancer. Carcinogenesis 25, 857-864 (2004). (Pubitemid 38886071)
42. Tomlinson, V. et al. JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis. Cell Death Dis. 1, e29 (2010).
43. Chaffer, C. L. et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 154, 61-74 (2013).
44. Barry, E. R. et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 493, 106-110 (2013).
45. Ehsanian, R. et al. YAP dysregulation by phosphorylation or DeltaNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets. Oncogene 29, 6160-6171 (2010).
46. Yuan, M. et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell. Death. Differ. 15, 1752-1759 (2008).
47. Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).
48. Zhang, Y. et al. Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma? Lung Cancer 81, 302-305 (2013).
49. Zhao, B. et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21, 2747-2761 (2007). (Pubitemid 350070721) Municipality